

**51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1 Name and Address of Company**

WPD Pharmaceuticals Inc. (the “Company”)  
Suite 1080, 789 West Pender Street  
Vancouver, BC V6C 1H2

**Item 2 Date of Material Change**

August 17, 2020.

**Item 3 News Release**

The news release dated August 17, 2020 was disseminated via Stockwatch and BayStreet on August 17, 2020.

**Item 4 Summary of Material Change**

The Company announced the appointment of Michael Malana of Richmond, B.C. as its CFO. Michael has considerable and continuous experience over the past 15 years acting as CFO, Corporate Controller and/or Corporate Secretary for a range of Canadian public companies listed on the TSX, TSXV and CSE. The Company is looking to Mr. Malana for his regulatory and stock exchange knowledge and for added value as a detailed and meticulous accountant.

The Company has accepted the resignation of Chris Cherry as CFO, who graciously agreed to be acting CFO starting in December 2019. The Company thanks Mr. Cherry for his service and wishes him well in future endeavours.

**Item 5 Full Description of Material Change**

*5.1 Full Description of Material Change*

The material change is fully described in Item 4 above and in the news release which has been filed on SEDAR on August 17, 2020.

*5.2 Disclosure for Restructuring Transactions*

N/A

**Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

N/A

**Item 7 Omitted Information**

None

**Item 8 Executive Officer**

Contact: Liam Corcoran, Canadian Vice President of Legal and Corporate Secretary  
Telephone: (604) 428-7050

**Item 9 Date of Report**

August 28, 2020